Rituximab Adult FRNS/SDNS (2025) — Trial Summary

Rituximab Adult FRNS/SDNS (2025): Multicenter, double-blind, randomized, placebo-controlled trial at 13 centers in Japan of intravenous rituximab 375 mg/m² versus placebo at weeks 1, 2, and 25 in adults with frequently relapsing or steroid-dependent nephrotic syndrome who were in remission (urine pr

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.